Mode
Text Size
Log in / Sign up
N/A N=73 Randomized Single-blind Treatment

A Behavioral Intervention for Depression and Chronic Pain in Primary Care

Chronic Pain · Depression

Enrolled (actual)
73
Serious AEs
5.5%
Results posted
Feb 2023
Primary outcome: Primary: Change in Clinically Significant Depressive Symptoms, as Measured by the Montgomery Asberg Depression Rating Scale (MADRS) — 19.37; 20.87; 14.88; 18.67 score on a scale — p=0.39

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
RELIEF (Behavioral)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Weill Medical College of Cornell University
Primary completion
Feb 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Clinically Significant Depressive Symptoms, as Measured by the Montgomery Asberg Depression Rating Scale (MADRS)
19.37; 20.87; 14.88; 18.67; 16.44; 18.00 0.39
PRIMARY
Change in Pain-related Disability, as Measured by the Roland-Morris Disability Questionnaire (RMDQ)
5.83; 6.57; 5.85; 6.47; 5.54; 6.60 0.17
PRIMARY
Client Satisfaction Questionnaire (CSQ)
3.40; 2.29; 3.72; 3.20; 3.67; 2.71 0.0003 sig
SECONDARY
Change in Mood, as Measured by the Daily Photographic Affect Meter (PAM)
2.83; 2.48; 2.58; 2.94
SECONDARY
Activities Monitoring
75947.60; 69557.39
SECONDARY
Activities Monitoring
75947.60; 69557.39

Summary

Chronic pain and depression frequently co-exist in late and mid-life and contribute to increased disability, high health care costs, psychiatric comorbidity, and suicide. The investigators will recruit 60 adults from Weill Cornell Medical Associates primary care practices; participants will be randomized to either Relief (a 9 session behavioral intervention) or usual care/referral for mental health care. Research assessments are conducted with both groups at study entry (Baseline), 6, 9, and 12 weeks.

Eligibility Criteria

Inclusion Criteria

  • Age 50 years
  • PHQ-9 greater than or equal to 10
  • Non-cancer related chronic pain, defined as pain during most days over the past 3 months by patient report
  • Capacity to consent

Exclusion Criteria

  • DSM-5 Axis 1 other than depression and anxiety disorders
  • Montreal Cognitive Assessment (MoCA) < 24
  • Active suicidal ideation, i.e. MADRS Suicide Item greater than or equal to 4
  • Severe or life-threatening medical illness.
  • Patients on psychotropics, opioids or benzodiazepines will be included if they do not meet DSM-5 criteria for opioid, anxiolytics or other substance abuse disorders
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03265210). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search